Company |
Product |
Description |
Indication |
Status |
Phase I | ||||
Amyndas Pharmaceuticals Inc., of Philadelphia |
AMY-101 |
C3-targeted complement inhibitor |
Complement-mediated conditions |
AMY-101 had a good safety profile in healthy male volunteers administered single and multiple doses; pharmacokinetic and pharmacodynamic characteristics support subcutaneous dosing every 48 hours |
Combioxin SA, of Geneva |
CAL-02 |
Broad-spectrum antitoxin |
Community-acquired pneumonia |
Completed first-in-man trial, with the independent data monitoring committee supporting a positive safety profile at both dosing regimens in patients with severe CAPB due to Streptococcus pneumoniae |
Phase II | ||||
Immunovaccine Inc., of Halifax, Nova Scotia |
DPX-Survivac |
Survivin-based peptide antigens |
Diffuse large B-cell lymphoma |
Initiated patient dosing in investigator-sponsored trial in combination with pembrolizumab (Keytruda, Merck & Co. Inc.) |
Mimedx Group Inc., of Marietta, Ga. |
Amniofix |
Composite amniotic tissue membrane |
Osteoarthritis of the knee |
Enrolled first patient in prospective, double-blind, randomized, controlled phase IIb study |
Phase III | ||||
Alnylam Pharmaceuticals Inc., of Cambridge, Mass. |
Patisiran |
RNAi therapeutic |
Hereditary ATTR amyloidosis |
Patisiran demonstrated improvement of cardiomyopathy in prospectively defined subgroup of patients with cardiac amyloid involvement, relative to placebo |
Brainstorm Cell Therapeutics Inc., of New York |
Nurown |
Cell therapy |
Amyotrophic lateral sclerosis |
Amended protocol so that Canada-based patients can enter |
Cytori Therapeutics Inc., of San Diego |
Cytori Cell Therapy |
Adipose-derived regenerative cells |
Stress urinary incontinence due to prostate intervention |
Full enrollment was reached in the 45-patient ADRESU investigator-initiated trial in Japan |
Edge Therapeutics Inc. |
EG-1962 |
Nimodipine microcapsules |
Aneurysmal subarachnoid hemorrhage |
Discontinued on advice from data monitoring committee |
Urovant Sciences |
Vibegron |
Oral β3-adrenergic agonist |
Overactive bladder |
Started EMPOWUR trial |
Wize Pharma Inc., of Hod Hasharon, Israel |
LO2-A |
Sodium hyaluronate |
Dry eye syndrome |
Enrolled the first patient in a phase IV trial to treat dry eye syndrome in patients with Sjogren's syndrome vs. Systane Ultra UD eye drop |
Notes For more information about individual companies and/or products, see Cortellis. |